Trial Profile
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUALIFY IPF
- Sponsors Boehringer Ingelheim
- 10 May 2023 Status changed from active, no longer recruiting to completed.
- 11 Mar 2022 Status changed from suspended to active, no longer recruiting.
- 08 Mar 2021 Planned End Date changed from 28 Mar 2022 to 28 Mar 2023.